PortalPublikationenWann sollten wir mit der medikamentösen Therapie beim Morbus...

Wann sollten wir mit der medikamentösen Therapie beim Morbus Parkinson beginnen?

Standard

Wann sollten wir mit der medikamentösen Therapie beim Morbus Parkinson beginnen? / Buhmann, C; Klucken, J; Korchounov, A; Schwarz, M; Vieregge, P; Jost, W H.

in: FORTSCHR NEUROL PSYC, Jahrgang 78 Suppl 1, 01.03.2010, S. S31-3.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung

Harvard

Buhmann, C, Klucken, J, Korchounov, A, Schwarz, M, Vieregge, P & Jost, WH 2010, 'Wann sollten wir mit der medikamentösen Therapie beim Morbus Parkinson beginnen?', FORTSCHR NEUROL PSYC, Jg. 78 Suppl 1, S. S31-3. https://doi.org/10.1055/s-0029-1245169

APA

Buhmann, C., Klucken, J., Korchounov, A., Schwarz, M., Vieregge, P., & Jost, W. H. (2010). Wann sollten wir mit der medikamentösen Therapie beim Morbus Parkinson beginnen? FORTSCHR NEUROL PSYC, 78 Suppl 1, S31-3. https://doi.org/10.1055/s-0029-1245169

Vancouver

Buhmann C, Klucken J, Korchounov A, Schwarz M, Vieregge P, Jost WH. Wann sollten wir mit der medikamentösen Therapie beim Morbus Parkinson beginnen? FORTSCHR NEUROL PSYC. 2010 Mär 1;78 Suppl 1:S31-3. https://doi.org/10.1055/s-0029-1245169

Bibtex

@article{346eb765c36f4c08aad679aca0c9be65,
title = "Wann sollten wir mit der medikament{\"o}sen Therapie beim Morbus Parkinson beginnen?",
abstract = "There is still uncertainty when to start medical treatment in Parkinson disease (PD). Lack of availability of an unambiguous neuroprotective treatment and concern of potential short or long term adverse effects of medication often lead to an {"}wait and see{"} policy regarding initiation of medical treatment. This can result in insufficient symptom control and potentially reduced quality of life. There is increasing evidence of negative influence on disease progression by delayed onset of medical drug treatment in PD. It is under discussion whether symptomatic treatment in PD supports compensatory mechanisms of the cortico-basalganglionar system which might have been responsible for a physically intact motor function despite considerable and increasing nigro-striatal dopaminergic deficit during the preclinical phase of the disease. Therefore, symptomatic treatment might modify disease progression by supporting compensatory mechanisms within the basal ganglia. In this paper we discuss pro and contra of early medical treatment onset in PD under consideration of hitherto available scientific investigations.",
keywords = "Antiparkinson Agents, Humans, Parkinson Disease, Time Factors",
author = "C Buhmann and J Klucken and A Korchounov and M Schwarz and P Vieregge and Jost, {W H}",
year = "2010",
month = mar,
day = "1",
doi = "10.1055/s-0029-1245169",
language = "Deutsch",
volume = "78 Suppl 1",
pages = "S31--3",
journal = "FORTSCHR NEUROL PSYC",
issn = "0720-4299",
publisher = "Georg Thieme Verlag KG",

}

RIS

TY - JOUR

T1 - Wann sollten wir mit der medikamentösen Therapie beim Morbus Parkinson beginnen?

AU - Buhmann, C

AU - Klucken, J

AU - Korchounov, A

AU - Schwarz, M

AU - Vieregge, P

AU - Jost, W H

PY - 2010/3/1

Y1 - 2010/3/1

N2 - There is still uncertainty when to start medical treatment in Parkinson disease (PD). Lack of availability of an unambiguous neuroprotective treatment and concern of potential short or long term adverse effects of medication often lead to an "wait and see" policy regarding initiation of medical treatment. This can result in insufficient symptom control and potentially reduced quality of life. There is increasing evidence of negative influence on disease progression by delayed onset of medical drug treatment in PD. It is under discussion whether symptomatic treatment in PD supports compensatory mechanisms of the cortico-basalganglionar system which might have been responsible for a physically intact motor function despite considerable and increasing nigro-striatal dopaminergic deficit during the preclinical phase of the disease. Therefore, symptomatic treatment might modify disease progression by supporting compensatory mechanisms within the basal ganglia. In this paper we discuss pro and contra of early medical treatment onset in PD under consideration of hitherto available scientific investigations.

AB - There is still uncertainty when to start medical treatment in Parkinson disease (PD). Lack of availability of an unambiguous neuroprotective treatment and concern of potential short or long term adverse effects of medication often lead to an "wait and see" policy regarding initiation of medical treatment. This can result in insufficient symptom control and potentially reduced quality of life. There is increasing evidence of negative influence on disease progression by delayed onset of medical drug treatment in PD. It is under discussion whether symptomatic treatment in PD supports compensatory mechanisms of the cortico-basalganglionar system which might have been responsible for a physically intact motor function despite considerable and increasing nigro-striatal dopaminergic deficit during the preclinical phase of the disease. Therefore, symptomatic treatment might modify disease progression by supporting compensatory mechanisms within the basal ganglia. In this paper we discuss pro and contra of early medical treatment onset in PD under consideration of hitherto available scientific investigations.

KW - Antiparkinson Agents

KW - Humans

KW - Parkinson Disease

KW - Time Factors

U2 - 10.1055/s-0029-1245169

DO - 10.1055/s-0029-1245169

M3 - SCORING: Zeitschriftenaufsatz

C2 - 20195939

VL - 78 Suppl 1

SP - S31-3

JO - FORTSCHR NEUROL PSYC

JF - FORTSCHR NEUROL PSYC

SN - 0720-4299

ER -